Latest Conference Articles

Paul Walfish, MD, professor emeritus at the University of Toronto School of Medicine, senior consult Mount Sinai Hospital discusses programmed death ligand 1 (PD-1) expression in aggressive metastatic papillary thyroid cancer.

A Japanese research team attempted to standardize therapy for anaplastic thyroid carcinoma by assessing the feasibility and efficacy of weekly paclitaxel administration.

A comprehensive review of patients receiving pembrolizumab has found an incidence of abnormal thyroid function tests as high as 15%.

Investigators at the Mount Sinai School of Medicine, Toronto, Canada, have been working on a potential correlation for aggressiveness and/or disease-free survival in thyroid cancer patients.

Patients who had prostate cancer recurrence after radical prostatectomy lived significantly longer with the addition of hormonal therapy to salvage radiotherapy, long-term follow-up from a randomized trial showed.

Michael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.

Intensity-modulated radiation therapy (IMRT) for cervical cancer has led to a double-digit decrease in late bowel toxicity compared with 3-D conformal radiation therapy without statistical significance.

Researchers have posited that well-differentiated thyroid cancers harbor distinct molecular pathological profiles that may be useful as prognostic indicators of future aggressiveness.

The rising overall risk of all sizes of malignant thyroid cancer has made clinicians question whether or not sub-centimeter thyroid nodules should also be biopsied.

While medullary thyroid cancer is not common as other thyroid cancers, it does have a poorer prognosis than these more common forms of metastatic thyroid cancer.

Ultra-hypofractionated radiation therapy for low-risk prostate cancer led to significantly lower rates of bowel and urinary dysfunction compared with patients treated with conventional radiotherapy regimens.

A novel serotonin synthesis inhibitor, telotristat etiprate, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care treatments, an encouraging sign for an emerging class of drugs.

Dr. Erin Murphy talks about a study presented by Dr. Thomas E. Merchant regarding young patients with ependymoma and how they can be treated effectively with a regiment of adjuvant radiation.

Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.

BRAF V600E is essential to the survival of many tumors and has been the focus of targeted therapeutics like a new BRAF V600E-selective inhibitor, which has been used for papillary thyroid carcinomas.

Keith Bible, MD, PhD, Mayo Clinic professor of oncology goes into detail about the current status of using VEGFR tyrosine kinase inhibitors to treat thyroid cancer.

Cabozantinib, an oral multikinase inhibitor, showed promise as second- or third-line therapy in patients with advanced differentiated thyroid cancer (DTC).

Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.

Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.

Dr. Nicole O. Vietor presented a report assessing practice discordances related to previously published guidelines published from the American Thyroid Association and the American Association of Clinical Endocrinologists.

A phase III study shows noninferiority of accelerated partial breast irradiation as compared to conventional whole breast irradiation.

Minesh Mehta, MBChB, talks about the recently FDA-approved Optune used to treat newly diagnosed glioblastoma. The device utilizes alternating electric fields to inhibit tumor cell growth.

Patients in a lenvatinib treatment arm with radioiodine-refractory differentiated thyroid cancer and certain metastasis experienced a much better overall median progression-free survival compared with a placebo arm.

Patients who received hypofractionated radiation therapy did not demonstrate statistically significant differences in long-term outcomes compared with patients who received conventional radiation therapy, according to a study .

Everolimus demonstrated a 52% reduction in the risk of progression or death in patients with lung/gastrointestinal neuroendocrine tumors, improving progression-free survival by 7.1 months compared with placebo.

The future of somatostatin analogs for neuroendocrine tumors (NETs) includes potential advances on several fronts, according to a presentation at the NANETS' 2015 Neuroendocrine Tumor Symposium.

Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.

Results from NETTER-1 trial showed an unprecedented 79% reduction in the risk of progression or death with the radiopharmaceutical Lu-Dotatate compared with high-dose octreotide LAR (60 mg) in patients with progressive, metastatic midgut neuroendocrine tumors (NETs).

Jay Ciezki, MD, staff member of the Department of Radiation Oncology at Cleveland Clinic and Department of Cell Biology at Cleveland Clinic, talks about the potential advantages of utilizing Stereotactic Body Radiation Therapy in prostate cancer patients.

Hypofractionation, known as delivering higher doses of radiation in fewer fractions, appears to be feasible and non-inferior compared with conventional fractionated radiotherapy.